8-K/A: CareDx Appoints New CFO, Adjusts Executive Compensation

CareDx, Inc. amends its prior 8-K filing to detail compensation adjustments for its newly appointed Chief Financial Officer, Keith Kennedy.

Summary

• This filing is an amendment (Amendment No. 2) to a previous Current Report on Form 8-K.
• It supplements the disclosure regarding the appointment of Keith Kennedy as Chief Financial Officer and Chief Operating Officer, effective February 26, 2026.
• The Compensation and Human Capital Committee approved compensation adjustments for Mr. Kennedy on April 20, 2026, in recognition of his expanded role.
• These adjustments include an award of 24,134 restricted stock units (RSUs) with a staggered vesting schedule.
• Additionally, 24,134 performance-based restricted stock units (PRSUs) were awarded, subject to performance conditions for 2026 and 2027, and time-based vesting.
• Mr. Kennedy's annual base salary of $613,000 and target bonus opportunity of 75% remain unchanged.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it clarifies executive compensation related to a key appointment, indicating ongoing management focus and incentive alignment, but does not present new operational or financial performance data.

Positives

• Executive compensation adjustments made to recognize expanded responsibilities.
• Award of restricted stock units (RSUs) and performance-based restricted stock units (PRSUs) to incentivize performance.
• Clear vesting schedules and performance conditions outlined for equity awards.
• Base salary and target bonus opportunity remain unchanged, indicating stability in core compensation.

Negatives

• Additional equity awards suggest a need to retain or motivate key executive talent in a potentially competitive environment.

Risks

• Performance-based vesting conditions for PRSUs introduce uncertainty regarding the realization of the full award.
• Continued service requirements for vesting mean that departure from the company prior to vesting dates could result in forfeiture of awards.

Future Outlook

The future outlook is tied to the performance-based vesting conditions of the PRSUs, which are contingent on achieving targets over the 2026 and 2027 performance periods. The continued service requirement also implies a focus on executive retention.

Management Comments

• In recognition of Mr. Kennedy's expanded responsibilities in assuming the additional role of Chief Financial Officer, on April 20, 2026, the Committee approved...

Industry Context

StockSavvy.ai notes that the issuance of equity awards, particularly performance-based units, is a common practice in the biotechnology and diagnostics sector to align executive incentives with company performance and shareholder value, especially during periods of executive role expansion.

Management Changes

Stakeholder Impact

• Shareholders: The equity awards are intended to align executive interests with shareholder value creation through performance-based incentives.
• Employees: The compensation structure for a key executive may influence overall compensation philosophy and retention strategies within the company.
• Management: Clarifies the compensation package for a critical executive role, providing transparency.

Next Steps

• Vesting of RSUs according to the specified schedule (starting April 6, 2027).
• Achievement of performance-based vesting conditions for PRSUs over the 2026 and 2027 performance periods.
• Continued service by Keith Kennedy to meet vesting requirements.

Key Dates

Keywords

CareDx, CDNA, 8-K/A, Amendment, Executive Compensation, Restricted Stock Units, Performance Shares, CFO Appointment